Skip to content
Menu

Trevi Therapeutics, Inc. TRVI

Full chart Compare
Set alert

Price alert · TRVI

All alert types
13.35 USD -0.37 (-2.70%)

Regular-session close

13.35 0.00 0.00%

After hours · Nov 20, 5:31 PM ET

13.23 Day range 13.90
9.82 52-week range 20.22
YTD
+6.63%
1 year
+25.35%

5D +0.27 (+2.01%)

1313.5014FriMonTueWedThu13.72
Market cap
1.90B
EPS (ttm)
-0.40
Shares out
142.56M
Forward P/E
-21.99
YTD return
+6.63%
1-year return
+25.35%
50-day average
13.78
200-day average
14.57
Enterprise value
1.66B
Price / book
6.29
Volume
2.09M
Avg volume
1.98M
Open
13.58
Previous close
13.72
Day's range
13.23 – 13.90
52-week range
9.82 – 20.22
Beta
1.12
Analysts
Strong Buy
Price target
28.18 (+111.1%)
Earnings date
Mar 16, 2027

Key statistics

Free cash flow
-37.97M
Total cash
299.41M
Total debt
527.00K
Return on equity
-24.67%
Short % of float
13.13%

Fundamental scorecard

3 of 25 checks passed on TRVI’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TRVI Revenue — quarterly 0
TRVI Net income — quarterly -21.45M
TRVI EPS — quarterly -0.13

Earnings

TRVI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 16, 2027Dec 30, 2026-0.15———
Nov 9, 2026Sep 30, 2026-0.13167-0.130.00+1.27%
Aug 6, 2026Jun 30, 2026-0.10946-0.110.00-0.49%
May 5, 2026Mar 31, 2026-0.07-0.09-0.02-28.57%
Mar 17, 2026Dec 31, 2025-0.10-0.06+0.04+40.00%
Nov 13, 2025Sep 30, 2025-0.10-0.08+0.02+20.00%

Upgrades / downgrades

TRVI analyst upgrades and downgrades
DateFirmActionFromTo
Aug 14, 2026Jones TradingmainBuyBuy
Aug 7, 2026OppenheimermainOutperformOutperform
Aug 7, 2026Cantor FitzgeraldmainOverweightOverweight
Jul 21, 2026BMO CapitalinitOutperformOutperform
Jul 20, 2026B. Riley SecuritiesmainBuyBuy
Jul 20, 2026HC Wainwright & Co.mainBuyBuy

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on TRVI — it syncs with the Stock Master app.

Insider holders

TRVI insider holders
InsiderRelationLatest transactionDateShares held
BASKETT FORESTBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityApr 16, 20250
BEHBAHANI ALIBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityApr 16, 20250
CHANG CARMENBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityApr 16, 20250
FLORENCE ANTHONY A JRBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityApr 16, 20250
GOOD JENNIFER LChief Executive OfficerSaleMar 20, 2025213,313
MAKHZOUMI MOHAMADBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityApr 16, 20250

Institution ownership

TRVI institution ownership
Holder% heldSharesValueReported
FMR, LLC9.56%13,630,034181.96MSep 29, 2026
NEA Management Company, LLC9.27%13,222,228176.52MSep 29, 2026
Blackrock Inc.8.62%12,288,233164.05MSep 29, 2026
Frazier Life Sciences Management, L.P. 6.69%9,539,147127.35MSep 29, 2026
Wellington Management Group, LLP4.37%6,236,26683.25MSep 29, 2026
Vanguard Capital Management LLC4.29%6,112,61681.60MSep 29, 2026

Fund ownership

TRVI fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.84%4,047,12554.03MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.98%2,819,88037.65MSep 29, 2026
MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund1.87%2,660,00035.51MJun 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio1.64%2,334,88531.17MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth Fund1.37%1,950,34126.04MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.95%1,353,31218.07MJun 29, 2026